This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk
by Zacks Equity Research
Using Omega's (OMGA) proprietary technology platform, Novo Nordisk (NVO) intends to develop a novel therapeutic for obesity, which will enhance the body's metabolism activity to burn excess fats.
Lilly (LLY) Starts Website to Help Access Tirzepatide Drugs
by Zacks Equity Research
Eli Lilly's (LLY) digital pharmacy is expected to provide patients easy access to its FDA-approved tirzepatide medicines, Mounjaro and Zepbound.
Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs
by Zacks Equity Research
Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.
Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals
by Kinjel Shah
Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.
Here's Why You Should Invest in Adverum (ADVM) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why buying Adverum Biotechnologies (AQST) stock now may turn out to be a prudent move.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $103.62, denoting a +1.48% change from the preceding trading day.
Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now
by Zacks Equity Research
Here, we discuss some reasons why buying Rigel Pharmaceuticals (RIGL) stock now may turn out to be a prudent move.
Here's Why You Should Invest in Aquestive (AQST) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why buying Aquestive Therapeutics (AQST) stock now may turn out to be a prudent move.
Eli Lilly (LLY) Stock Up 57% in 2023: Will the Uptrend Continue?
by Zacks Equity Research
Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.
The Zacks Analyst Blog Highlights Novo Nordisk, Walmart, Advanced Micro Devices, Caterpillar and Union Pacific
by Zacks Equity Research
Novo Nordisk, Walmart, Advanced Micro Devices, Caterpillar and Union Pacific are part of the Zacks top Analyst Blog.
Top Analyst Reports for Novo Nordisk, Walmart & AMD
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Walmart Inc. (WMT) and Advanced Micro Devices, Inc. (AMD).
Why You Should Invest in Encompass Health (EHC) Stock for Now
by Zacks Equity Research
Encompass Health (EHC) is well-poised for growth on the back of growing revenues, an aging U.S. population, joint ventures and solid cash reserves.
Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy
by Zacks Equity Research
Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals
by Zacks Equity Research
After a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug.
Universal Health (UHS) Up 17% in 3 Months: More Growth Ahead?
by Zacks Equity Research
Universal Health (UHS) is well-poised for growth on the back of the resumption of elective procedures, acquisitions and solid operating cash flows.
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA
by Zacks Equity Research
Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.
FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab
by Zacks Equity Research
The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
by Kinjel Shah
Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.
Pfizer (PFE) Stock Rises on FDA Nod for Expanded Use of Padcev
by Zacks Equity Research
The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
by Zacks Equity Research
Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.
Alexandria (ARE) Inks Leases at its Campuses Amid Solid Demand
by Zacks Equity Research
Amid the booming demand for life-science assets, Alexandria (ARE) inks leases with Novo Nordisk and CARGO at its mega campuses in Greater Boston and San Carlos in the San Francisco Bay Area.
The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK
by Zacks Equity Research
Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK are included in this Analyst Blog.
5 Big Drug Stocks That May Continue to Outperform in 2024
by Kinjel Shah
Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
5 Non-U.S. Stocks to Buy as Wall Street Fires on All Cylinders
by Nalak Das
We have selected five high-flying non-U.S. companies that have strong potential for 2024. These are: NVO, NTES, TM, PDD, STLA.